跳至主要内容
临床试验/CTRI/2018/09/015772
CTRI/2018/09/015772尚未招募2 期

Investigating the efficacy of dual stimulation of tDCS and rTMS Neuro-modulation therapy of Major depression

Director NIMHANS1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2018年1月10日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
140
试验地点
1
主要终点
1.Clinical scores: HDRS, MADRS, CGI,

研究概览

简要总结

Majordepression is the commonest psychiatric disorder affecting 3-5% of Indianpopulation. Although the exact pathophysiology of these disordersis unknown, drugs acting on several neurotransmitter systems such as serotoninand norepinephrine tend to clinically improve the condition in 30-50% patients.However, recurrence or relapses and partial response are common in thisdisabling condition (~30-40%) requiring second line of treatmentstrategies or add-on/adjuvant therapies. In this regard, there is expandinginterest in repetitive transcranial magnetic stimulation (rTMS) andtranscranial direct current stimulation (tDCS) as add-on to standard medicaltherapies for this disabling psychiatric disorder. Although thesetwo modes of non-invasive brain stimulation have been successfully consideredas second or third lines of antidepressant managements, we are still lackingthe clear understanding of combining these two modes of non-invasive modes ofstimulation. Further neurophysiological modulation of excitability and plasticitywhen brain stimulation is being used as therapeutic strategies in patients withMajor depression has not been studied. Based on scientific studies, we knowthat anodal and cathodal tDCS alter the excitability of stimulated region in anopposite direction in such a way that anodal facilitates long-term potentiation(LTP)-like and cathodal tDCS facilitates long-term depression (LTD)-likeneuroplasticity of the stimulated region. Similarly high (>5Hz)and low (<1Hz) frequency rTMS increases or decreases the excitability of thestimulated region through plasticity effects. However, when thesetwo modes of stimuli are given one after the other, metaplasticity sets in,resulting in changed direction of the excitability to maintain the homeostaticplasticity based on the Bienenstock--Cooper--Munro model.Thus when two protocols, which produce LTP effects are combined (say anodaltDCS and high frequency rTMS), the resultant homeostatic plasticity will bringdown the excitability in such a way that finally resulting in LTD-like effect.Hence we propose to use cathodal tDCS instead of anodal to potentiate theeffect of high frequency rTMS to left dorsolateral prefrontal cortex (DLPFC) toobtain increased excitability effects in patients with Major depression. Thesemetaplastic effects have been validated in healthy subjects andpatients with migraine and also in the visual cortex.Further, the neurobiological factors and patient characteristics contributingto efficacy of these add-on antidepressant therapies in refractory depressionis not established. Hence we plan to study the efficacy of dual stimulation oftDCS and high frequency rTMS at DLPFC as potential and efficaciousantidepressant therapies. We would also like to use the metaplasticity effectsat M1 as a predictor of efficacy for the dual stimulation along with othermeasures: heart rate variability (HRV) and TMS measures of excitability.

研究设计

研究类型
Interventional
分配方式
Permuted block randomization, fixed
盲法
Participant and Outcome Assessor Blinded

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Individuals with a diagnosis of moderate or severe depression according to ICD-10 diagnosed by a psychiatrist would be recruited if they continue to have at least moderate depressive symptoms as defined clinically and using the HDRS cut-off score of more than 17 even after at least 4-weeks of adequate antidepressant trial with any conventional antidepressant medication.

排除标准

  • 1.Patients aged < 18 and > 60 years of age 2.If patient is on any psychotropic (other than antidepressant medications, which is kept constant throughout the study period unless clinically required), anticholinergic or cardiac medications 3.Patients with suicidal tendencies or psychotic depression 4.Patients with any co-morbid cardiac or neurological disorders that can increase the risk of TMS related complications or are having a contraindication for TMS/tDCS treatment 5.Pregnant/lactating patients 6.Failure of other organ systems or systemic illness that could affect autonomic function or participants’ ability to cooperate.

结局指标

主要结局

1.Clinical scores: HDRS, MADRS, CGI,

时间窗: Baseline, 15 days and 2 months after the start of neuromodulation therapy

2.HRV measures: both time and frequency domain measures of heart rate variability

时间窗: Baseline, 15 days and 2 months after the start of neuromodulation therapy

3.Cortical excitability and plasticity measures

时间窗: Baseline, 15 days and 2 months after the start of neuromodulation therapy

4. Metaplasticity effects of tDCS-rTMS on M1

时间窗: Baseline, 15 days and 2 months after the start of neuromodulation therapy

次要结局

  • 1. HRV measures: both time and frequency domain measures of heart rate variability(2.Cortical excitability and plasticity measures)

研究者

发起方
Director NIMHANS
申办方类型
Research institution and hospital

研究点 (1)

Loading locations...

相似试验